Isaac E. Ciechanover Sells 8,800 Shares of Atara Biotherapeutics (ATRA) Stock

Atara Biotherapeutics (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,800 shares of the company’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $42.13, for a total transaction of $370,744.00. Following the transaction, the chief executive officer now directly owns 812,613 shares of the company’s stock, valued at $34,235,385.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:ATRA opened at $39.95 on Wednesday. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $49.90.

How to Become a New Pot Stock Millionaire

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($1.15). analysts expect that Atara Biotherapeutics will post -3.62 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ATRA. MetLife Investment Advisors LLC purchased a new position in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $217,000. Nexthera Capital LP acquired a new position in shares of Atara Biotherapeutics in the 4th quarter valued at $5,188,000. Raymond James & Associates grew its position in Atara Biotherapeutics by 7.3% in the 4th quarter. Raymond James & Associates now owns 25,325 shares of the biotechnology company’s stock valued at $458,000 after buying an additional 1,719 shares during the last quarter. Bridger Management LLC grew its position in Atara Biotherapeutics by 57.3% in the 4th quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company’s stock valued at $47,035,000 after buying an additional 946,086 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in Atara Biotherapeutics by 4.6% in the 4th quarter. California State Teachers Retirement System now owns 42,159 shares of the biotechnology company’s stock valued at $763,000 after buying an additional 1,836 shares during the last quarter. Institutional investors and hedge funds own 76.88% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Citigroup cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a report on Thursday, February 15th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. JMP Securities downgraded shares of Atara Biotherapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 28th. Guggenheim started coverage on shares of Atara Biotherapeutics in a research report on Thursday, March 15th. They set a “neutral” rating on the stock. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, March 13th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $37.50.

TRADEMARK VIOLATION NOTICE: “Isaac E. Ciechanover Sells 8,800 Shares of Atara Biotherapeutics (ATRA) Stock” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/11/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-8800-shares.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply